P a

t i

e n


c a

r e

DePartMental organisation

The Clinic is divided into specialised teams with particular expertise in the manage- ment of site-specific cancers, such as breast, gynaecological, thoracic, head and neck, genito-urinary, and rare tumours.

There are 3 medical oncologists on staff. In addition, each year the department hosts an average of 6 interns and residents, junior doctors who are being trained in medical oncology.

The cases of all patients needing treatment with anticancer drugs are presented and discussed during weekly multidisciplinary rounds.

Every possible effort is made to offer all patients the opportunity to participate in clinical trials, since these provide both optimal medical care as well as access to new therapies that are potentially more effective, or are associated with fewer side effects.

This dynamic approach to treatment requires the medical oncology staff to partici- pate actively in cancer research organisations, such as the European Organisation for Research and Treatment of Cancer.

Another key responsibility of the medical oncologists on staff lies in training interns and residents. This is done on an ongoing basis by supervising their clinical activities and by regularly holding educational seminars and workshops.

KeY Figures

658 new patients hospitalised/year 13,000 patients seen in consultations/year

120 ongoing clinical trials


Missions Offering to each cancer patient at risk of relapse or presenting

with advanced disease the best possible therapy with anticancer drugs to prevent the development or slow the progression of metastases

Managing promptly and optimally all the side effects induced by these therapies, in case preventive measures fail

Prof Martine Piccart Medical Oncologist, Head of Medicine Department

Prof Ahmad Awada Medical Oncologist, Head of Clinic

Quality of care in the field of medical oncology requires constant interaction with other disciplines, in particular nursing, pathology (for in-depth characterisation of the molecular profile of each tumour, which guides doctors in the selection of the best anticancer drug), tumour imaging (for the rigorous evaluation of disease status and response or lack of response to the selected anticancer therapy), infectiology (to rapidly treat infectious complications of certain therapies), and supportive care (to minimise the side effects of anticancer drugs). In addition, continual dialogue with other cancer disciplines such as radiotherapy and surgical oncology makes it possibly to rapidly identify combined treatment approaches, which are often more effective than single treatment types.

FielD, technologies anD MethoDs